Intuity Legal » News Archives

Legal 500 & Chambers 2015 : INTUITY still leading firm

Sandra LELEUX — Thu, 14 May 2015 09:02:21 +0000

Legal 500 EMEA 2015

INTUITY has been recommended as a TOP-TIER FIRM in Healthcare and life sciences practice area

Chambers Europe 2015

INTUITY is ranked in Band 2 in Pharma / Lifesciences practice area

See all rankings

Palmarès des Avocats: Intuity wins the Silver Trophy

Sandra LELEUX — Sun, 29 Mar 2015 17:40:33 +0000

For the second consecutive year, Intuity wons the silver trophy in the category “lifesciences and healthcare”.

This award takes on particular significance as the Firm celebrates this year its tenth anniversary.

We thank you all for your continued confidence.

http://www.lepalmaresdesavocats.fr/

Class actions : coming soon in French hospitals ?

Sandra LELEUX — Sun, 29 Mar 2015 17:17:11 +0000

Read Intuity and Public Voice’s analysis for Réseau CHU

http://www.reseau-chu.org/les-articles/article/article/class-actions-les-actions-de-groupe-bientot-dans-les-hopitaux-francais/

DMLA : “Ménage à trois” ?

Sandra LELEUX — Sun, 29 Mar 2015 16:59:19 +0000

On March 24, the French competent authority (ANSM) authorized Avastin®, as part of an TUA (Temporary Use Authorisation) in the treatment of macular degeneration related to age (AMD).

In France, two products are indicated : Lucentis (Novartis ) and Eylea® (Bayer). Avastin, whose cost is lower than the cost of the other two drugs, does not have this indication. He was prescribed off-label in many countries.

As we mentioned in the January issue of our Newsletter, this decision comes at a particularly competitive environment. Roche and Novartis have, indeed, been convicted of anti competitive agreements in several States and investigations are ongoing in others. These Laboratories have disseminated information to promote the sales of Lucentis at the expense of Avastin®, including reliance on artificial differences between the two products and suggesting that off-label use of Avastin, could present some risks, where Lucentis was developed by a subsidiary of Roche, who continues to receive royalties on sales of Novartis …

The evolution of the prescriptions will be decisive.

(FR) Communications électroniques: le Conseil d’Etat consacre le principe de la « focalisation » dans le secteur de la santé

Sandra LELEUX — Tue, 10 Mar 2015 20:22:10 +0000

Sorry, this entry is only available in FR.

La Revue Parlementaire – Special Issue “What future for our healthcare system?”

Sandra LELEUX — Tue, 10 Mar 2015 19:36:22 +0000

In its special issue dated march 2015, the journal interviewed C. Hénin on the stakes and challenges the pharmaceutical industry will face

Download the PDF Special Issue – March 2015

2 nd meetup Health 2.0. Paris

Sandra LELEUX — Tue, 10 Mar 2015 10:09:18 +0000

On 11 march 2014, INTUITY will address the issue “Pharma Industry: obstacle or driving force for innovation?” with speakers from the industry and helath 2.0. start ups.

Come and meet us at Numa from 19 h to 20 h 30.

Program and registration http://suqj.mj.am/nl/suqj/sq6jt.html

(FR) Circulaire Loi Hamon : explication de texte

Sandra LELEUX — Mon, 19 Jan 2015 15:43:11 +0000

Getting the Deal Through – Life Sciences Edition 2015

Antigone — Mon, 19 Jan 2015 10:50:20 +0000

The 2015 Edition is now online.

Read the French Chapter written by INTUITY

Consulter le PDF

Health 2.0 Paris 26 November 2014

Antigone — Wed, 26 Nov 2014 14:54:50 +0000

INTUITY participated to the first Health 2.0. Conference of the French Chapter held at Numa, on 26/11/2014 in Paris

See the video the 26 Novembre 2014 conference
- Download the flyer